Furosemide After Childbirth in Women With Severe Preeclampsia, Compared With Placebo
Tests furosemide against placebo in women with severe preeclampsia after giving birth.
Plain-language title generated from the registry record
Registry title: Furosemide vs Placebo in Severe Preeclampsia Postpartum
Key facts
- Where
- Tegucigalpa, HondurasSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 49 years old?
Source: NCT07648251, who can take part
Where in Honduras
- Hospital EscuelaTegucigalpa, HondurasNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Nacional Autonoma de Honduras
- Trial code
- NCT07648251
- Record updated
- 5 November 2026
- Original description
This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.Read full original descriptionShow less
Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial
This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.
Inclusion: Signed informed consent (assent for minors 14-17 years with parental/guardian consent); Confirmed severe preeclampsia (BP ≥160/110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral/visual symptoms); Postpartum (12-24 hours after delivery, vaginal or cesarean); Hemodynamically stable (no vasopressors for ≥6 hours); Preserved diuresis (>30 mL/hour for ≥6 hours); Serum creatinine <0.8 mg/dL.
Exclusion: Pregnancy (current - not applicable postpartum, but excludes undiagnosed concurrent pregnancy); Known allergy to sulfonamides or furosemide; Active febrile illness; Known chronic kidney disease (eGFR <60 mL/min/1.73m²); Current or chronic diuretic use (before or during pregnancy); Participation in another interventional trial.